Business Model Breakdown
How PAVmed Inc Makes Money
PAVM
Market Cap
$46M
Annual Revenue
$22,000
Profit Margin
564.8%
Employees
39
The Short Version
PAVmed Inc. is a medical technology company focused on developing and commercializing innovative medical devices and diagnostics. Its primary value resides in its majority-owned subsidiary, Lucid Diagnostics, which offers EsoGuard, a DNA test for the early detection of esophageal precancer (Barrett's Esophagus) using the EsoCheck capsule-based sample collection device. PAVmed also has Veris Health, which is developing implantable cardiac monitors for remote patient monitoring. The company aims to generate revenue through the sale of EsoGuard tests and, in the future, Veris Health devices and associated services.
Where the Revenue Comes From
EsoGuard test sales (Lucid Diagnostics) (~100% of reported 'segment revenue', $1.3M in Q1 2026)
Other negligible consolidated PAVmed Inc. revenue ($22k in Q1 2026)
Who buys: Healthcare providers (gastroenterologists, primary care physicians, cardiologists) and patients at risk for esophageal cancer or requiring cardiac monitoring.
Why It Works (Competitive Advantages)
- ✔Proprietary technology and intellectual property for EsoGuard and EsoCheck devices for Barrett's Esophagus screening.
- ✔FDA clearances and regulatory pathways established for EsoGuard.
Economic Moat: None (Intangible Assets/IP)
What Our Analysis Says
DVR Score as of May 25, 2026
PAVmed Inc. remains an extremely speculative investment. While Lucid Diagnostics (a subsidiary) shows nascent commercial progress with $1.3M in Q1 2026 EsoGuard revenue and 3,177 tests processed, PAVmed Inc.'s consolidated financial health is critically weak. The Q1 2026 report reveals only $6.5 million in cash and equivalents against $8.1 million in quarterly operating expenses, implying a cash runway of less than one quarter. This immediate liquidity concern for the parent company, coupled with negligible direct revenue and ongoing high burn, warrants a significantly lower score. The path to 10x growth hinges entirely on an accelerated, sustained commercialization ramp for EsoGuard and successful Veris Health launch, but the company must first secure substantial new financing to survive, likely at the cost of significant shareholder dilution.